BDNF and retinal degeneration: Given that a substantial portion of patients with long-term anti-VEGF therapies appeared to have very thin retinas [16,19], a key characteristic of retinal degeneration, identifying neuroprotectant, such as BDNF which is a VEGF downstream target with no apparent harm to the retina, is paramount to the improvement of anti-VEGF therapies.